Human Papillomavirus Isolated from Transplant-Associated Porokeratoses of Mibelli Responsive to Topical 5% Imiquimod Cream

Esser, Adam C.; Pittelkow, Mark R.; Randle, Henry W.

doi:10.1111/j.1524-4725.2006.32176.x

Cited by 15 publications

(5 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Anecdotal reports have also described topical imiquimod's potential in the treatment of other cutaneous and mucosal disorders as summarized in Table …”

Section: Off‐label Uses Of Imiquimod In Cutaneous Disordersmentioning

confidence: 99%

Imiquimod in dermatology: an overview

2016

View full text Add to dashboard Cite

Imiquimod is an immune response modifier commercially available as a 3.75 and 5% cream. Topical imiquimod stimulates the innate and adaptive immune responses and induces cytokine production. This allows its use for the treatment of a wide variety of benign and malignant skin conditions due to its potential antiviral, antitumor, and immunoregulatory effects. Currently, topical imiquimod is US Food and Drug Administration (FDA)-approved for the treatment of anogenital warts, actinic keratosis, and superficial basal cell carcinomas. However, it has also shown a beneficial effect in the treatment of many other skin disorders. In this review, we describe existing evidence on the mechanism of action of topical imiquimod, its FDA-approved indications, off-label uses, and side effects.

show abstract

“…Anecdotal reports have also described topical imiquimod's potential in the treatment of other cutaneous and mucosal disorders as summarized in Table …”

Section: Off‐label Uses Of Imiquimod In Cutaneous Disordersmentioning

confidence: 99%

Imiquimod in dermatology: an overview

2016

View full text Add to dashboard Cite

show abstract

“…Topical 5% imiquimod cream provided excellent outcomes in nine PM cases [140,346,353,[363][364][365][366][367][368] and no response in three [340,342,369].…”

Section: Treatmentmentioning

confidence: 99%

Porokeratoses—A Comprehensive Review on the Genetics and Metabolomics, Imaging Methods and Management of Common Clinical Variants

Pietkiewicz,

Korecka,

Salwowska

et al. 2023

Metabolites

View full text Add to dashboard Cite

Porokeratosis is a heterogeneous group of keratinising disorders characterised by the presence of particular microscopic structural changes, namely the presence of the cornoid lamella. This structure develops as a consequence of a defective isoprenoid pathway, critical for cholesterol synthesis. Commonly recognised variants include disseminated superficial actinic porokeratosis, disseminated superficial porokeratosis, porokeratosis of Mibelli, palmoplantar porokeratosis (including porokeratosis palmaris et plantaris disseminata and punctate porokeratosis), linear porokeratosis, verrucous porokeratosis (also known as genitogluteal porokeratosis), follicular porokeratosis and porokeratoma. Apart from the clinical presentation and epidemiology of each variant listed, this review aims at providing up-to-date information on the precise genetic background, introduces imaging methods facilitating the diagnosis (conventional and ultraviolet-induced fluorescence dermatoscopy, reflectance confocal microscopy and pathology), discusses their oncogenic potential and reviews the literature data on the efficacy of the treatment used, including the drugs directly targeting the isoprenoid–mevalonate pathway.

show abstract

“…55 Several case reports suggest that topical application of imiquimod might be effective in inactivating HPV and treating BP. [56][57][58][59] Recent clinical data indicates that the combined modality of multiple sessions of imiquimod (4 weeks) and ALA-PDT (1-4 times) is tolerable, effective and associated with a low incidence of recurrence. 60…”

Section: B Combined Pdt With Imiquimod For Pre-malignant and Malignamentioning

confidence: 99%

Combination of photodynamic therapy and immunomodulation: Current status and future trends

Qiang

Yow

Huang

2007

Medicinal Research Reviews

View full text Add to dashboard Cite

Photodynamic therapy (PDT) has been used for the treatment of non-malignant and malignant diseases from head to toe. Over the last decade its clinical application has gained increasing acceptance around the world. Pre-clinical studies demonstrate that, in addition to the direct local cytotoxicity and vascular effects, PDT can induce various host immune responses. Recent clinical data also show that improved clinical outcomes are obtained through the combination of PDT and immunomodulation. This review will summarize and discuss recent progress in developing innovative regimen of PDT combined with immunomodulation for the treatment of both nonmalignant and malignant diseases.

show abstract

Human Papillomavirus Isolated from Transplant-Associated Porokeratoses of Mibelli Responsive to Topical 5% Imiquimod Cream

Abstract: have indicated no significant interest with commercial supporters.

Cited by 15 publications

References 26 publications

Imiquimod in dermatology: an overview

Imiquimod in dermatology: an overview

Porokeratoses—A Comprehensive Review on the Genetics and Metabolomics, Imaging Methods and Management of Common Clinical Variants

Combination of photodynamic therapy and immunomodulation: Current status and future trends

Contact Info

Product

Resources

About